The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles

Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50% of the patients who receive the most intensive treatment develop chemoresistant leukemia relapse. Although the leukemogenic events leading to relapse seem to differ between patients (i.e., regrowth from a clone detect...

Descripción completa

Detalles Bibliográficos
Autores principales: Aasebø, Elise, Berven, Frode S., Hovland, Randi, Døskeland, Stein Ove, Bruserud, Øystein, Selheim, Frode, Hernandez-Valladares, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352627/
https://www.ncbi.nlm.nih.gov/pubmed/32512867
http://dx.doi.org/10.3390/cancers12061466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352627/
https://www.ncbi.nlm.nih.gov/pubmed/32512867
http://dx.doi.org/10.3390/cancers12061466

Ejemplares similares